5WUV
 
 | | Crystal structure of Certolizumab Fab | | Descriptor: | heavy chain, light chain | | Authors: | Heo, Y.S, Lee, J.U, Son, J.Y, Shin, W, Yoo, K.Y. | | Deposit date: | 2016-12-21 | | Release date: | 2017-06-07 | | Method: | X-RAY DIFFRACTION (1.952 Å) | | Cite: | Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Int J Mol Sci, 18, 2017
|
|
4Y7I
 | | Crystal Structure of MTMR8 | | Descriptor: | Myotubularin-related protein 8, PHOSPHATE ION | | Authors: | Yoo, K, Lee, J, Son, J, Shin, W, Im, D, Heo, Y.S. | | Deposit date: | 2015-02-15 | | Release date: | 2015-07-15 | | Last modified: | 2024-03-20 | | Method: | X-RAY DIFFRACTION (2.802 Å) | | Cite: | Structure of the catalytic phosphatase domain of MTMR8: implications for dimerization, membrane association and reversible oxidation.
Acta Crystallogr.,Sect.D, 71, 2015
|
|
5WUX
 | | TNFalpha-certolizumab Fab | | Descriptor: | Tumor necrosis factor alpha, heavy, light | | Authors: | Heo, Y.S, Lee, J.U. | | Deposit date: | 2016-12-21 | | Release date: | 2017-06-07 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Int J Mol Sci, 18, 2017
|
|
5Y9J
 | | BAFF in complex with belimumab | | Descriptor: | Tumor necrosis factor ligand superfamily member 13B, belibumab light chain, belimumab heavy chain | | Authors: | Heo, Y.-S, Shin, W. | | Deposit date: | 2017-08-25 | | Release date: | 2018-02-21 | | Last modified: | 2019-09-04 | | Method: | X-RAY DIFFRACTION (2.05 Å) | | Cite: | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
5Y9K
 | | Structure of the belimumab Fab fragment | | Descriptor: | belimumab heavy chain, belimumab light chain | | Authors: | Heo, Y.-S, Shin, W. | | Deposit date: | 2017-08-25 | | Release date: | 2018-02-21 | | Last modified: | 2019-09-04 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
